Alaunos Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Alaunos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q2 2024.
  • Alaunos Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$1.17M, a 85.4% increase year-over-year.
  • Alaunos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$19.5M, a 43.3% increase year-over-year.
  • Alaunos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$34.3M, a 2.39% increase from 2022.
  • Alaunos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$35.1M, a 54.7% increase from 2021.
  • Alaunos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$77.5M, a 3.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$19.5M -$1.17M +$6.82M +85.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$26.3M -$1.74M +$7.93M +82% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$34.3M -$7.95M +$574K +6.74% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$34.8M -$8.66M -$400K -4.84% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$34.4M -$7.98M +$1.25M +13.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$35.7M -$9.67M -$587K -6.46% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$35.1M -$8.52M +$2.53M +22.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$37.6M -$8.26M +$14M +62.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$51.7M -$9.23M +$13.4M +59.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$65.1M -$9.09M +$12.5M +57.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$77.5M -$11.1M +$11.7M +51.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-07
Q3 2021 -$89.3M -$22.3M -$1.98M -9.72% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$87.3M -$22.6M -$4.03M -21.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$83.3M -$21.6M -$2.9M -15.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$80.4M -$22.8M -$6.74M -42% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$73.6M -$20.3M -$6.87M -51.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$66.8M -$18.6M -$3.85M -26.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$62.9M -$18.7M -$5.04M -37% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$57.9M -$16M -$3.27M -25.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$54.6M -$13.4M -$878K -6.99% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$53.7M -$14.8M -$2.38M -19.2% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$51.3M -$13.6M +$2.58M +15.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$53.9M -$12.8M +$674K +5.02% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$54.6M -$12.6M +$508K +3.88% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$55.1M -$12.4M +$636K +4.89% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$55.7M -$16.2M -$2.23M -16% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$53.5M -$13.4M -$2.33M -20.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-05
Q3 2017 -$51.2M -$13.1M -$2.16M -19.8% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-05
Q2 2017 -$49M -$13M +$118M +90.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-05
Q1 2017 -$167M -$14M -$1.93M -16% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-05
Q4 2016 -$165M -$11.1M -$1.63M -17.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$164M -$10.9M +$7.25M +39.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$171M -$131M -$117M -823% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$53.9M -$12M +$66.2M +84.6% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$120M -$9.48M +$1.11M +10.5% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-16
Q3 2015 -$121M -$18.2M -$6.22M -52.1% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-16
Q2 2015 -$115M -$14.2M -$3.05M -27.3% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-16
Q1 2015 -$112M -$78.2M -$68.4M -700% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-16
Q4 2014 -$43.5M -$10.6M -$3.88M -57.7% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-24
Q3 2014 -$39.6M -$11.9M -$2.83M -31% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-24
Q2 2014 -$36.8M -$11.2M +$7.12M +38.9% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-24
Q1 2014 -$43.9M -$9.78M +$13.8M +58.5% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-24
Q4 2013 -$57.7M -$6.72M +$32.1M +82.7% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-26
Q3 2013 -$89.8M -$9.12M +$12.6M +58% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-26
Q2 2013 -$102M -$18.3M +$4.67M +20.3% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-26
Q1 2013 -$107M -$23.6M -$4.95M -26.6% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-26
Q4 2012 -$102M -$38.8M -$22.4M -137% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-03
Q3 2012 -$79.7M -$21.7M -$7.52M -52.9% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-03
Q2 2012 -$72.2M -$23M -$10.1M -78.8% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-03
Q1 2012 -$62.1M -$18.6M +$9.29M +33.3% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-03
Q4 2011 -$71.4M -$16.4M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$14.2M -$5.71M -67.2% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$12.8M -$7.73M -151% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 -$27.9M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$8.5M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 -$5.12M Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.